QuantalX Neuroscience has introduced the new Delphi-MD device for the early detection and subtyping of Parkinson's disease.

The device, part of the company’s extensive neurological disease diagnostic portfolio, employs direct electrophysiological imaging technology to provide real-time insights into brain network function.  

This system can identify specific physiological changes within brain networks, particularly the occipital networks, which manifest during the initial stages of the disease.

It will enable healthcare professionals to pinpoint patients who may experience rapid disease progression. This capability facilitates early intervention and tailored treatment plans.

Furthermore, Delphi-MD's advanced technology allows for the early and accurate detection of Parkinson's neurophysiological subtypes by recognising distinct electrophysiological alterations in crucial brain networks.

By acknowledging the individuality of each Parkinson's patient, the device significantly minimises diagnostic time and uncertainty.

This innovation is poised to transform clinical practice by refining treatment selection and disease monitoring.

It offers clinicians real-time insights for personalised therapeutic strategies, thereby improving patient care.

NINDS, NIH Human Motor Control Section former chief professor Mark Hallett said: "Delphi-MD represents a leap forward in our ability to confirm the diagnosis of Parkinson's disease at an earlier stage. The precision and clarity it provides in detecting subtle brain network changes could revolutionise how we approach treatment and patient care."

With Delphi-MD's verified ability to detect network dysfunctions associated with Parkinson's, it is expected to revolutionise the way healthcare systems and pharmaceutical companies approach diagnosis and treatment selection. 

QuantalX leverages the new Direct Neuro-Physiological technology, the Delphi-MD device, to improve patient care and reduce the burden on healthcare systems.